Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved
Authors:
- Alberto Polo-BarrancoAPAlberto Polo-Barranco
- Carlos Rebolledo-MaldonadoCRCarlos Rebolledo-Maldonado
- Dairo Rodelo-BarriosDRDairo Rodelo-Barrios
- Juan Solano-RoperoJSJuan Solano-Ropero
- Valentina Rada-ObesoVRValentina Rada-Obeso
- Carlos Lavalle-JiménezCLCarlos Lavalle-Jiménez
- Valeria Blanchar-MartínezValeria Blanchar-Martínez
- Carlos Beltran-SánchezCBCarlos Beltran-Sánchez
- Augusto Maza-ArnedoAMAugusto Maza-Arnedo
- Thalia Herrera-CalvoTHThalia Herrera-Calvo
- Isaias Hazbun-CaicedoIHIsaias Hazbun-Caicedo
- Muna Isaac-EscorciaMIMuna Isaac-Escorcia
Preprint
- 26 June 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.Keywords
All Related Versions
This publication has 93 references indexed in Scilit:
- Sex differences of lipoprotein(a) in individuals aged 18-90 years – A nationwide study of 149,000 individualsAtherosclerosis, 2025
- Lipoprotein(a) and Calcific Aortic Valve Stenosis ProgressionJAMA Cardiology, 2024
- Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2024
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationJAMA, 2023
- Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population StudyAtherosclerosis, 2022
- Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?Basic Research in Cardiology, 2022
- Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The Copenhagen General Population StudyAtherosclerosis, 2022
- Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept studyInternal and Emergency Medicine, 2018
- Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysisAtherosclerosis, 2015
- Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve stenosisAtherosclerosis, 2014